Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2022-05-01
Sarja:Vaccines
Aiheet:
pneumococcal vaccination
immunocompromised host
transplant recipient
autoimmune disease
vaccine immunogenicity
Linkit:https://www.mdpi.com/2076-393X/10/5/795

Internet

https://www.mdpi.com/2076-393X/10/5/795

Samankaltaisia teoksia